Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Zuellig Pharma, officially known as Zuellig Pharma Holdings Pte Ltd, is a leading provider of research and development services within the healthcare sector. Headquartered in Singapore, the company operates extensively across Asia, serving key markets in the region. Since its founding in 1915, Zuellig Pharma has established a strong reputation for delivering innovative solutions in pharmaceutical distribution, clinical research, and healthcare logistics.
Specialising in research and development services, Zuellig Pharma focuses on advancing healthcare through customised solutions that support pharmaceutical innovation and patient care. Its extensive network and expertise position it as a notable player in the industry, recognised for its commitment to quality and operational excellence. With a history of strategic growth and a focus on technological advancement, Zuellig Pharma continues to shape the future of healthcare services in Asia.
+19 vs industry average
Zuellig Pharma’s score of 49 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research Services has below-average carbon intensity
The Research Services industry has reduced its overall emissions by 19% since 2018
Scope 3 accounts for ••• of total emissions.
Zuellig Pharma, headquartered in Singapore, is a company operating in research and development services. In 2024, the company reported total greenhouse gas emissions of approximately 232.3 million kg CO2e. This figure comprises approximately 14.7 million kg CO2e for Scope 1 emissions and around 22.2 million kg CO2e for Scope 2 emissions (market-based). Scope 3 emissions accounted for approximately 165.4 million kg CO2e.
The company's emissions data for 2024 shows significant contributions from purchased goods and services (approximately 79.3 million kg CO2e) and upstream transportation and distribution (approximately 68.0 million kg CO2e) within Scope 3.
Zuellig Pharma has established several climate commitments. Notably, the company aims to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030, using 2021 as a baseline year. Furthermore, it has committed to a 25% reduction in absolute Scope 3 GHG emissions specifically for fuel and energy-related activities, upstream transportation and distribution, and waste generated in operations, also by 2030.
In the longer term, Zuellig Pharma is aligning with national and regional targets, aiming for carbon neutrality by 2050 in line with Hong Kong's objectives and by 2060 according to national targets.
The emissions data for Zuellig Pharma is inherited from its parent organisation, Zuellig Pharma Holdings, as it is a current subsidiary.
Access structured emission data, company specific factors and auditable source documents
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more